Shots:

• ReNeuron to receive £6.0M ($7.9M) upfront- £6.0M ($7.9M) near-term milestones- £8.0M ($10.5M) regulatory milestones and post-launch profit threshold milestones of 5% on annual profit- leading to total milestones £80.0M ($104.8M) and 12%-14% royalties on net sales of product in China
• Fosun to get exclusive rights to develop and commercialize ReNeuron’s CTX and hRPC cell therapy in China. Additionally- ReNeuron will take care to supply CTX and hRPC cells to Fosun during the transition period
• ReNeuron’s hRPC cell therapy is based on human retinal progenitor cells and is evaluated in P-I/IIa trial in patients with retinitis pigmentosa (RP) in the US with its expected results in H1’19. CTX therapy is currently evaluated in P-I for limb ischaemia

Ref: ReNeuron | Image: WSJ